Baseimmune, an innovative biotech firm pioneering the use of AI in vaccine development, has secured £9M in a Series A financing endeavour. The injection of capital is spearheaded by MSD Global Health Innovation Fund and IQ Capital, further buoyed by contributions from stalwart supporters such as Hoxton Ventures and Maki.vc. This financial infusion propels Baseimmune's mission to preemptively tackle infectious diseases through advanced vaccine designs that anticipate pathogen evolution.